Coupled with Morgan Stanley Private Equity Asia, Sihuan delisted from SGX.

Acquisition of 60% of the equity of Shandong Sihuan Institute.

Kelinao was the best selling drug in the Chinese Pharmaceutical market.

More than a dozen new products were launched, such as Aogan and Aipukang.

Beijing Sihuan Pharmaceutical Co., Ltd was granted the “National High-tech Enterprise” status and Hainan Sihuan Pharmaceutical Co., Ltd successfully renewed its “National New and High Tech Enterprise” status, both enjoy 15% preferable tax rate.

Sihuan Pharmaceutical Group was listed on the mainboard of the Singapore Stock Exchange on 23 March.

Acquisition of 100% of the equity of Shenzhen Sihuan.

Beijing Sihuan Pharmaceutical Co., Ltd was given a second research and development grant for RMB 1million from the Beijing Municipal Science and Technology Commission (北京市科学技术委员会) for pre-clinical research on coronary heart disease treatment drug-G20.

Kelinao was ranked No. 1 in terms of the total sales among peripheral vascular drugs marketed in China and was granted “State Torch Programme” status by the Science and Technology Ministry.

Hainan Sihuan Pharmaceutical Co., Ltd was granted the “National High-tech Enterprise” status.

Hainan Sihuan Cardio-cerebral Vascular Drugs Research Institute was founded.

Acquisition of remaining equity of Beijing Sihuan for a 100% stake.

Kelinao was included in the official Medicine Catalogues in 26 provinces.

Sihuan Pharmaceutical Group was granted a 20-year patent protection on Kelinao.

A Product Evaluation Committee was set up within the company.

Acquisition of 28% of the Beijing Sihuan’s equity.

Kelinao and Saimeiao were launched.

Hainan Sihuan Pharmaceutical Co., Ltd. was founded.